Hanmi Pharmaceutical Co., Ltd. 128940
KRX · South Korea · Health Technology
KRW 497,500.00-1,500.00 (-0.30%)
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
MegazoneCloud (CEO Doug Yeum), a leading AI and cloud company, is undertaking the development of 'Hanmi Q-Agent,' an AI agent that automates Hanmi Pharmaceutical's quality assurance (QA) operations, based on its enterprise AI OS 'AIR Studio.'
The licensing deal marks a diversification of Roche’s obesity pipeline as it seeks entry into the lucrative market.
For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.